The Committee believes that all therapeutic strategies listed in this section ("Salaries in development") will be the subject of further research before they can be determine their usefulness in MS. Currently, there can be used recommended outside clinical trials planning correctly.
While there are undoubtedly necessary tools to develop effective strategies for highly treatment of MS, it would be wise to give a lot of optimism was premature and approach new therapeutic based on the results of studies on a small scale, without the completion of the third phase of studies on more staff. This shows the situation through the latter case of roquinimex (LinomideMD), immunoprecipitation, promising results completed in two phases Studies II, but unfortunately at the time of the third phase of tests had to be taken, involving more than 1,500 patients, because we realized that he had a severe toxicity and cardiovascular. In the case of a disease such as MS, which is characterized by progressive deterioration of the deficit for many years, and serious side effects, even if they are rare, lasting impact on the development of new therapeutic.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.